Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314547 | 0.91 | MEN1 (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1062476 | 0.90 | RAB9A (0.42) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1064168 | 0.89 | KMT2A (0.43) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12962918 | 0.88 | RAB9A (0.41) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1058637 | 0.87 | RAB9A (0.43) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1062495 | 0.86 | GAA (0.41) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1062226 | 0.84 | ADORA2B (0.39) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1062094 | 0.84 | ALDH1A1 (0.45) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10314446 | 0.83 | KDM4E (0.47) | RAB9ASMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL1062712 | 0.83 | ALDH1A1 (0.39) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | RAB9A 2411/4885KMT2A 386/4885MEN1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.